Jesús Troya García

41PUBLICATIONS
277CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMedical molecular engineering of nucleic acids and proteinsAboriginal and Torres Strait Islander medicine and treatmentsBehavioural epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Oct 24, 2026
Immune Trajectories After Switch to Long-Acting Cabotegravir Plus Rilpivirine in the RELATIVITY Cohort.

|Oct 23, 2026
Long-term Effectiveness, Treatment Persistence, and Timing of Virological Failure With Long-Acting Cabotegravir Plus Rilpivirine in Real-World HIV Care: RELATIVITY Cohort.

|Jul 16, 2026
Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort.

|Apr 21, 2026
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

|Jan 25, 2026
Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Jesús Troya, Rafael Mican, María José Galindo

|Oct 23, 2025
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).

Luis Buzón-Martín, Maria Luisa Montes, Roberto Pedrero

Pageof 7

Frequent Collaborators

14 joint publications

Luis Buzón-Martín

8 joint publications

Carmen Hidalgo-Tenorio

6 joint publications

Jean-Laurent Casanova

6 joint publications

Paul Bastard